BUZZ-Tvardi rises as oral inflammation drug shows early-stage trial promise

Tvardi Therapeutics Inc.

TVRD

0.00

** Shares of drug developer Tvardi Therapeutics TVRD.O rise 2% to $2.03 premarket

** Co says its oral experimental drug TTI-109 showed results in an early-stage study that were comparable to its earlier STAT3-targeting drug, TTI-101

** Says TTI-109 is being developed for diseases linked to inflammation and abnormal cell growth through the STAT3 protein

** Tvardi says TTI-109 reduced certain immune cells by up to 60%, a finding it believes supports further development

** Company said side effects were mild, with diarrhea lasting less than half a day versus more than three days with TTI-101

** As of last close, stock was down ~53% YTD

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.